| Literature DB >> 31957964 |
Taka-Aki Hirose1, Hidetaka Arimura2, Jun-Ichi Fukunaga1, Saiji Ohga3, Tadamasa Yoshitake3, Yoshiyuki Shioyama3.
Abstract
PURPOSE: There remain uncertainties due to inter- and intraobserver variability in soft-tissue-based patient positioning even with the use of image-guided radiation therapy (IGRT). This study aimed to reveal observer uncertainties of soft-tissue-based patient positioning on cone-beam computed tomography (CBCT) images for prostate cancer IGRT.Entities:
Keywords: PTV margin; interobserver variation; intraobserver variation; prostate cancer image-guided radiation therapy; soft-tissue-based patient positioning
Mesh:
Year: 2020 PMID: 31957964 PMCID: PMC7021001 DOI: 10.1002/acm2.12817
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1The evaluation scheme of residual errors by each observer on pre‐cone‐beam computed tomography image of a fraction.
Figure 2Residual errors between soft‐tissue positioning errors and reference positioning errors by six observers in anterior–posterior, superior–inferior, and left–right directions.
Figure 3Systematic errors of interobserver variations by six observers in anterior–posterior, superior–inferior, and left–right directions.
Figure 4Random errors of interobserver variations by six observers in anterior–posterior, superior–inferior, and left–right directions.
Figure 5Planning target volume margins calculated from the systematic and random errors of interobserver and/or intraobserver variations in anterior–posterior, superior–inferior, and left–right directions.
Comparison of target and OAR dose parameters for 30 validation patients in the treatment plans with PTVCL used in clinical practice and PTVST obtained from the PTV margins required for soft‐tissue‐based registration in this study.
| Volume of interest | Parameter | PTVCL | PTVST |
|
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| PTVCL or PTVST | D98 | 91.75 ± 1.31 | 91.71 ± 1.31 | n.s. |
| D95 | 95.93 ± 0.74 | 96.06 ± 0.88 | n.s. | |
| CI | 1.02 ± 0.03 | 0.99 ± 0.02 | <0.05 | |
| HI | 0.11 ± 0.01 | 0.11 ± 0.01 | n.s. | |
| CTV | D98 | 99.18 ± 0.29 | 99.19 ± 0.23 | n.s. |
| D95 | 99.62 ± 0.22 | 99.60 ± 0.18 | n.s. | |
| Rectum | V40 | 20.33 ± 4.69 | 14.85 ± 4.15 | <0.05 |
| V60 | 9.20 ± 2.80 | 5.50 ± 1.99 | <0.05 | |
| V65 | 6.82 ± 2.24 | 3.77 ± 1.50 | <0.05 | |
| V70 | 4.09 ± 1.55 | 2.01 ± 0.96 | <0.05 | |
| V75 | 0.63 ± 0.73 | 0.20 ± 0.29 | <0.05 | |
| Bladder | V40 | 25.12 ± 8.85 | 19.33 ± 8.37 | <0.05 |
| V70 | 10.40 ± 3.93 | 6.68 ± 3.34 | <0.05 | |
| V75 | 7.72 ± 3.01 | 4.47 ± 2.33 | <0.05 |
CI, conformity index; CTV, clinical target volume; Dn, dose received by n% of the volume; HI, homogeneity index; OAR, organs at risk; PTV, planning target volume; Vm, volume receiving at least m Gy dose.
n.s. = not significant (P > 0.05).